Heron Therapeutics
HRTX
186 hedge funds and large institutions have $510M invested in Heron Therapeutics in 2022 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 60 increasing their positions, 46 reducing their positions, and 19 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
63% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 19
59% more capital invested
Capital invested by funds: $321M → $510M (+$188M)
30% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 46
22% more call options, than puts
Call options by funds: $593K | Put options by funds: $487K
7% more funds holding
Funds holding: 174 → 186 (+12)
6.34% more ownership
Funds ownership: 112.48% → 118.82% (+6.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$33.4M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$22.1M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$12.2M |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$9.85M |
| 5 |
Millennium Management
New York
|
+$5.67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$29.3M |
| 2 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$28.3M |
| 3 |
Morgan Stanley
New York
|
-$4.27M |
| 4 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$4.1M |
| 5 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
-$3.35M |
HRTX Hedge Fund Activity: Q3 2022 in Review
186 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q3 2022, worth a combined $510M — up 59% from $321M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new HRTX positions and 19 closed out — a net gain of 12 holders — while 60 added to existing stakes and 46 trimmed.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $33.4M. The largest seller was State Street, cutting an estimated $29.3M.
- 186 institutional investors held Heron Therapeutics (HRTX) as of Q3 2022, up from 174 in Q2 2022.
- Funds reported $510M of Heron Therapeutics stock for Q3 2022, up 59% quarter-over-quarter.
- 31 funds opened new Heron Therapeutics positions in Q3 2022 and 19 closed out, a net change of +12 holders.
- The largest Heron Therapeutics buyer in Q3 2022 was Deep Track Capital, an estimated $33.4M added.
- The largest Heron Therapeutics seller in Q3 2022 was State Street, an estimated $29.3M sold.
Based on aggregated 13F filings for Q3 2022.